

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property  
Organization  
International Bureau



(43) International Publication Date  
7 April 2005 (07.04.2005)

PCT

(10) International Publication Number  
**WO 2005/030761 A1**

(51) International Patent Classification<sup>7</sup>: **C07D 409/12**,  
235/08, 413/12, 403/12, 401/04, 405/14, A61K 31/4184,  
A61P 25/00

(21) International Application Number:  
PCT/GB2004/004112

(22) International Filing Date:  
24 September 2004 (24.09.2004)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
0302570-7 26 September 2003 (26.09.2003) SE

(71) Applicant (for all designated States except MG, US): **ASTRAZENECA AB** [SE/SE]; S-151 85 Södertälje (SE).

(71) Applicant (for MG only): **ASTRAZENECA UK LIMITED** [GB/GB]; 15 Stanhope Gate, London Greater London W1K 1LN (GB).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **LIU, Ziping** [CA/CA]; AstraZeneca R & D Montréal, 7171 Fredrick-Banting, St Laurent, Québec H4S 1Z9 (CA). **MILBURN, Claire** [CA/CA]; AstraZeneca R & D Montréal, 7171 Fredrick-Banting, St Laurent, Québec H4S 1Z9 (CA). **PAGÉ, Daniel** [CA/CA]; AstraZeneca R & D Montréal, 7171 Fredrick-Banting, St Laurent, Québec H4S 1Z9 (CA). **TREMBLAY, Maxime** [CA/CA]; AstraZeneca R & D Montréal, 7171 Fredrick-Banting, St Laurent, Québec

H4S 1Z9 (CA). **WALPOLE, Christopher** [GB/CA]; AstraZeneca R & D Montréal, 7171 Frederick-Banting, St Laurent, Québec H4S 1Z9 (CA). **YANG, Hua** [CA/CA]; AstraZeneca R & D Montréal, 7171 Frederick-Banting, St Laurent, Québec H4S 1Z9 (CA).

(74) Agent: **GLOBAL INTELLECTUAL PROPERTY**; AstraZeneca AB, S-151 85 Södertälje (SE).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.


(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— with international search report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: **BENZIMIDAZOLE DERIVATIVES, COMPOSITIONS CONTAINING THEM, PREPARATION THEREOF AND USES THEREOF**



(57) Abstract: Compounds of Formula (I) or pharmaceutically acceptable salts thereof; wherein R<sup>1</sup>, R<sup>2</sup>, R<sup>3</sup>, R<sup>4</sup>, n and Ar are as defined in the specification as well as salts and pharmaceutical compositions including the compounds are prepared. They are useful in therapy, in particular in the management of pain.

WO 2005/030761 A1